College of Pharmacy, University of Rhode Island, Kingston.
Infectious Diseases Research Program, Providence Veterans Affairs Medical Center, Providence, Rhode Island.
Clin Infect Dis. 2018 Jul 2;67(2):303-309. doi: 10.1093/cid/ciy064.
Enterococci, one of the most common causes of hospital-associated infections, are responsible for substantial morbidity and mortality. Enterococcus faecalis, the more common and virulent species, causes serious high-inoculum infections, namely infective endocarditis, that are associated with cardiac surgery and mortality rates that remained unchanged for the last 30 years. The best cures for these infections are observed with combination antibiotic therapy; however, optimal treatment has not been fully elucidated. It is the purpose of this review to highlight treatment options and their limitations, and provide direction for future investigative efforts to aid in the treatment of these severe infections. While ampicillin plus ceftriaxone has emerged as a preferred treatment option, mortality rates continue to be high, and from a safety standpoint, ceftriaxone, unlike other cephalosporins, promotes colonization with vancomycin resistant-enterococci due to high biliary concentrations. More research is needed to improve patient outcomes from this high-mortality disease.
肠球菌是医院获得性感染的最常见原因之一,可导致严重的发病率和死亡率。其中,更常见且毒力更强的粪肠球菌可引起严重的高接种量感染,如感染性心内膜炎,与心脏手术相关,且 30 年来死亡率一直保持不变。这些感染的最佳治疗方法是联合使用抗生素治疗;然而,最佳治疗方法尚未完全阐明。本文旨在强调治疗选择及其局限性,并为未来的研究工作提供指导,以帮助治疗这些严重感染。氨苄西林加头孢曲松已成为首选治疗方案,但死亡率仍然很高,而且从安全性角度来看,与其他头孢菌素不同,头孢曲松由于胆汁浓度高,促进了耐万古霉素肠球菌的定植。需要更多的研究来改善这种高死亡率疾病患者的预后。